StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note released on Thursday morning. The firm issued a sell rating on the medical research company’s stock.
Organovo Trading Up 2.7 %
ONVO stock opened at $1.15 on Thursday. The company’s 50 day simple moving average is $1.04 and its 200-day simple moving average is $1.13. Organovo has a 12 month low of $0.89 and a 12 month high of $2.23.
Organovo (NASDAQ:ONVO – Get Free Report) last announced its quarterly earnings data on Thursday, February 8th. The medical research company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.08 million. As a group, analysts predict that Organovo will post -1.74 EPS for the current fiscal year.
Hedge Funds Weigh In On Organovo
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Stories
- Five stocks we like better than Organovo
- Why Are Stock Sectors Important to Successful Investing?
- Comprehensive PepsiCo Stock Analysis
- How to Capture the Benefits of Dividend Increases
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How to Calculate Inflation Rate
- Bear Market Funds to Watch This Year
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.